Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.
Document Type
Article
Publication Title
Haematologica
Abstract
Measurable residual disease (MRD) analysis using circulating tumor DNA (ctDNA) is a non-invasive method of response assessment in large B-cell lymphoma (LBCL), but data supporting its real-world feasibility and performance are needed. We conducted a multicenter, retrospective study of patients with LBCL assessed in real time with a commercially available, immunoglobulin rearrangement-targeted ctDNA-MRD assay (clonoSEQM). Our primary objective was to assess post-treatment MRD after immunochemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy. Median time from sample collection to MRD result was 9 days. Following frontline treatment (N=102), 12-month progression-free survival (PFS) was 15% versus 85% for detectable versus undetectable MRD (HR 14.5, p.
DOI
10.3324/haematol.2026.300901
Publication Date
8-13-2026
Recommended Citation
Gould P, Coskey D, Ma X, Wang S, Godbole S, Bond D, Ip A, Ananth S, Varma S, Ayers E, Faden R, Gillespie C, William B, Jacobs R, Hu B, Lattin J, Russler-Germain D, Stanchina M, Rose A, Randall M, Spinner M, Srikakulapu V, Geethakumari PR, Skarbnik A, Chitty DW, Tsang M, Duarte C, Major A, Bock AM, Baron K, Hess B, Tolu S, Pro B, Vaidya S, Amengual JE, Reshef R, Cherng HJ. Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes. Haematologica. 2026 Aug 13. doi: 10.3324/haematol.2026.300901. Epub ahead of print. PMID: 42610418.